C4 Therapeutics, Inc.

United States · Biotechnology

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. The company focuses on developing innovative therapies for cancer treatment and is listed on the NASDAQ under the ticker symbol CCCC. C4 Therapeutics specializes in targeted protein degradation through its proprietary platform, TORPEDO (Target-Oriented Protein Degrader Optimizer). This platform enables the creation of small-molecule medicines that degrade disease-causing proteins by utilizing the body's natural protein recycling system. The company's lead product, cemsidomide, is an oral MonoDAC degrader targeting IKZF1 and IKZF3 proteins, aimed at treating multiple myeloma and non-Hodgkin’s lymphoma. Other products in development include CFT1946 for V600 mutant cancers and CFT8919 for non-small cell lung cancer, along with additional undisclosed cancer treatment programs. C4 Therapeutics collaborates with major pharmaceutical companies such as Roche, Biogen, Betta Pharmaceuticals, Merck, and Merck KGaA, emphasizing its commitment to advancing cancer research and development through strategic partnerships.